Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

ritonavir 1,3-thiazol-5-ylmethyl N-[(2S,3S,5R)-3...

Synonyms: Norvir, Ritonavire, CHEMBL163, SureCN6679, Norvir Sec, ...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

High impact information on ritonavir

RESULTS: Simultaneous coadministration of ESO 20 mg qd with either FPV 1400 mg bid or FPV 700 mg bid + RTV 100 mg bid had no effect on steady-state amprenavir pharmacokinetics [1].

Associations of ritonavir with other chemical compounds

Human immunodeficiency virus protease inhibitor ritonavir significantly inhibits cholesterol efflux from macrophages, which may be mediated by mitochondrial dysfunction, oxidative stress, ERK1/2 activation, and down-regulation of scavenger receptor B1 and caveolin-1 [2].
Acute and steady-state ritonavir increased the fexofenadine AUC(0-infinity) 2.8- and 1.4-fold, respectively, suggesting P-gp inhibition [3].

Analytical, diagnostic and therapeutic context of ritonavir

Baseline viral load and the number of mutations on the protease coding region (PRO) were associated with the virological outcome of APV/RTV-based regimens [4].

References

Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. Shelton, M.J., Ford, S.L., Borland, J., Lou, Y., Wire, M.B., Min, S.S., Xue, Z.G., Yuen, G. J. Acquir. Immune Defic. Syndr. (2006) [Pubmed]
Human immunodeficiency virus protease inhibitor ritonavir inhibits cholesterol efflux from human macrophage-derived foam cells. Wang, X., Mu, H., Chai, H., Liao, D., Yao, Q., Chen, C. Am. J. Pathol. (2007) [Pubmed]
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Kharasch, E.D., Bedynek, P.S., Walker, A., Whittington, D., Hoffer, C. Clin. Pharmacol. Ther. (2008) [Pubmed]
Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients. Clevenbergh, P., Boulmé, R., Kirstetter, M., Dellamonica, P. HIV Med. (2004) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.